Integra LifeSciences Holdings Corp (IART) stock
Close on Nov 13, 2026Market cap $1.12BP/E 84.7Yield –
Integra LifeSciences Holdings Corp grew revenue 0.8% to $1.66B over the twelve months to Sep 30, 2026. Free cash flow was $85.78M. At the latest close the market valued the company at $1.12B, 84.7 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.12B
- P/E ratio
- 84.7
- Price to sales
- 0.68
- Price to book
- 1.05
- Dividend yield
- –
- Free cash flow yield
- 7.66%
Fundamentals
- Revenue
- $1.66B
- Net income
- $13.01M
- EPS, diluted
- $0.17
- Free cash flow
- $85.78M
- Book value per share
- $13.57
- Diluted shares
- 79M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $14.35
- Open
- $14.42
- Day's range
- $14.15 – $14.62
- Volume
- 648,838
- Average volume (20 days)
- 1,239,040
- Index membership
- S&P SmallCap 600 (since Aug 2024), Russell 2000 (since Sep 2024), Russell 3000
- Beta (5 years)
- 1.25
- 52-week range
- $8.70 – $20.49
- RSI (14 days)
- 54.3
- Volatility (1 year)
- 61.3%
- Relative volume
- 0.65×
- WACC
- 11.4%
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | IART | S&P 500 | Difference | IART per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +4.0% | -3.0% | +7.0 pts | ||
| 3 months | -21.1% | -2.8% | −18.3 pts | ||
| Year to date | +15.9% | +11.5% | +4.5 pts | ||
| 1 year | +19.6% | +13.5% | +6.1 pts | ||
| 3 years | -60.7% | +77.7% | −138.4 pts | -26.7% | +21.1% |
| 5 years | -78.9% | +72.6% | −151.5 pts | -26.7% | +11.5% |
| 10 years | -63.8% | +308.2% | −372.0 pts | -9.7% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Integra LifeSciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 GuidanceResults
- Update
- Results
About Integra LifeSciences
Surgical & Medical Instruments & Apparatus
Integra LifeSciences Holdings Corporation manufactures and sells medical technologies across two main business segments: Codman Specialty Surgical and Tissue Technologies. The specialty surgical segment supplies neurosurgical devices, neuro-monitoring systems, cranial stabilization equipment, ultrasonic tissue ablation tools, surgical headlamps, and specialty handheld instruments. The tissue technologies segment provides regenerative biomaterials, collagen implants, porcine matrices, human placental allografts, and dressings for wound management, plastic reconstruction, and general surgery. The company also produces private-label products for other medical firms. Its customers include hospitals, outpatient surgery centers, wound clinics, integrated health networks, and medical practices.
Company profile, executives and historyIntegra LifeSciences stock: common questions
What is Integra LifeSciences's stock price?
IART closed at $14.40 on Nov 13, 2026, up 0.35% on the day. Over the past 52 weeks it traded between $8.70 and $20.49.
What is Integra LifeSciences's market cap?
Integra LifeSciences was worth $1.12B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is IART's P/E ratio?
IART trades at 84.7 times earnings, based on diluted earnings per share of $0.17 over the twelve months to Sep 30, 2026.
How much revenue does Integra LifeSciences make?
Integra LifeSciences reported revenue of $1.66B for the twelve months to Sep 30, 2026, up 0.8% from a year earlier.
Does Integra LifeSciences pay a dividend?
No. Integra LifeSciences has not paid a cash dividend over the last twelve months.
When does Integra LifeSciences report earnings next?
Integra LifeSciences is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IART stock performed over the past year?
Including dividends, IART returned +19.6% over the past year, against +13.5% for the S&P 500.
How many IART shares are sold short?
8M shares were sold short at the latest FINRA report, 10.51% of the float, or 6.4 days of average trading volume.
Who are Integra LifeSciences's competitors?
Companies most similar to Integra LifeSciences by business, industry and size include MMSI, TFX, HAE, PEN, ICUI.
See a number that looks wrong?